Generic Ambien Assaults Sanofi’s Top Line, But Lantus Growth Offsets Drop In Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Net sales fell 6 percent in the fourth quarter, but plummeting Ambien IR revenues are counteracted by 30 percent rise in insulin brand Lantus.
You may also be interested in...
Sanofi’s Menactra Use Expanded To Children
Sanofi Pasteur’s meningococcal conjugate vaccine approved for use in children 2 years to 10 years old.
Generic Ambien To Launch Immediately Following FDA Approval
FDA approves the first generic versions of Sanofi-Aventis’ immediate-release zolpidem.
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.